Drug-Based Therapeutic Strategies for COVID-19-Infected Patients and Their Challenges

References

• Bavinger JC , ShanthaJG, YehS. Ebola, COVID-19, and emerging infectious disease: lessons learned and future preparedness. Curr. Opin. Ophthalmol.31(5), 416–422 (2020).
   PubMed Web of Science ®Google Scholar
• Roychoudhury S , DasA, SenguptaPet al. Viral pandemics of the last four decades: pathophysiology, health impacts and perspectives. Int. J. Environ. Res. Public Health17(24), 9411 (2020).
   PubMed Web of Science ®Google Scholar
• Paules CI , MarstonHD, FauciAS. Coronavirus infections – more than just the common cold. JAMA323(8), 707–708 (2020).
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P , Borhani-HaghighiA, KarimzadehIet al. Major neurologic adverse drug reactions, potential drug–drug interactions and pharmacokinetic aspects of drugs used in COVID-19 patients with stroke: a narrative review. Ther. Clin. Risk Manag.16, 595 (2020).
   PubMed Web of Science ®Google Scholar
• Tarus B , BertrandH, ZeddaG, DiPrimo C, QuideauS, Slama-SchwokA. Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of influenza A virus. J. Biomol. Struct. Dyn.33(9), 1899–1912 (2015).
   PubMed Web of Science ®Google Scholar
• Padhi AK , TripathiT. Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation. Biochem. Biophys. Res. Commun.555, 147–153 (2021).
   PubMed Web of Science ®Google Scholar
• Padhi AK , TripathiT. Can SARS-CoV-2 accumulate mutations in the S-protein to increase pathogenicity?ACS Pharmacol. Transl. Sci.3(5), 1023–1026 (2020).
   PubMedGoogle Scholar
• Mahmoud DB , ShituZ, MostafaA. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?J. Genet. Eng. Biotechnol.18(1), 1–10 (2020).
   PubMed Web of Science ®Google Scholar
• Struyf T , DeeksJJ, DinnesJet al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst. Rev.7(7), CD013665 (2020).
   PubMed Web of Science ®Google Scholar
• Pardi N , HoganMJ, PorterFW, WeissmanD. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discovery17(4), 261–279 (2018).
   PubMed Web of Science ®Google Scholar
• Turner JS , O'halloranJA, KalaidinaEet al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature596(7870), 109–113 (2021).
   PubMed Web of Science ®Google Scholar
• Lundstrom K . Viral vectors for COVID-19 vaccine development. Viruses13(2), 317 (2021).
   PubMed Web of Science ®Google Scholar
• Kalita P , PadhiAK, ZhangKYJ, TripathiT. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb. Pathog.145, 104236 (2020).
   PubMed Web of Science ®Google Scholar
• World Health Organization . COVID-19 vaccines (2021). http://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
   Google Scholar
• Kordzadeh-Kermani E , KhaliliH, KarimzadehI. Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). Future Microbiol.15(13), 1287–1305 (2020).
   PubMed Web of Science ®Google Scholar
• Hoehl S , RabenauH, BergerAet al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N. Engl. J. Med.382(13), 1278–1280 (2020).
   PubMed Web of Science ®Google Scholar
• Billah MA , MiahMM, KhanMN. Reproductive number of coronavirus: a systematic review and meta-analysis based on global level evidence. PLoS ONE15(11), e0242128 (2020).
   PubMed Web of Science ®Google Scholar
• Wang M , CaoR, ZhangLet al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res.30(3), 269–271 (2020).
   PubMed Web of Science ®Google Scholar
• Yang SN , AtkinsonSC, WangCet al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res.177, 104760 (2020).
   PubMed Web of Science ®Google Scholar
• Meo SA , Al-KhlaiwiT, UsmaniAM, MeoAS, KlonoffDC, HoangTD. Biological and epidemiological trends in the prevalence and mortality due to outbreaks of novel coronavirus COVID-19. J. King Saud. Univ. Sci.32(4), 2495–2499 (2020).
   PubMed Web of Science ®Google Scholar
• Rothan HA , ByrareddySN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun.109, 102433 (2020).
   PubMed Web of Science ®Google Scholar
• Smith RD . Responding to global infectious disease outbreaks: lessons from SARS on the role of risk perception, communication and management. Soc. Sci. Med.63(12), 3113–3123 (2006).
   PubMed Web of Science ®Google Scholar
• Bai HX , HsiehB, XiongZet al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology296(2), e46–e54 (2020).
   PubMed Web of Science ®Google Scholar
• De Groot RJ , BakerSC, BaricRSet al. Commentary: Middle East Respiratory Syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group. J. Virol.87(14), 7790–7792 (2013).
   PubMed Web of Science ®Google Scholar
• Mubarak A , AlturaikiW, HemidaMG. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J. Immunol. Res.2019, 6491738 (2019).
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P , Mohammadi-SamaniS. The necessity of early anti-inflammatory therapy initiation in cases with mild-to-moderate COVID-19: a personal experience from an attending pharmacist and his resident. Acta Bio-medica: Atenei Parmensis92(3), e2021250–e2021250 (2021).
   PubMedGoogle Scholar
• Hui DS , AzharEI, MadaniTAet al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. J. Glob. Infect. Dis.91, 264–266 (2020).
   Google Scholar
• Clerkin KJ , FriedJA, RaikhelkarJet al. COVID-19 and cardiovascular disease. Circulation141(20), 1648–1655 (2020).
   PubMed Web of Science ®Google Scholar
• Guo T , FanY, ChenMet al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol.5(7), 811–818 (2020).
   PubMed Web of Science ®Google Scholar
• Mao L , JinH, WangMet al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol.77(6), 683–690 (2020).
   PubMed Web of Science ®Google Scholar
• Filatov A , SharmaP, HindiF, EspinosaPS. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus12(3), e7352 (2020).
   PubMed Web of Science ®Google Scholar
• Wu P , DuanF, LuoCet al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol.138(5), 575–578 (2020).
   PubMed Web of Science ®Google Scholar
• Galván Casas C , CatalaA, CarreteroHernández Get al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br. J. Dermatol.183(1), 71–77 (2020).
   PubMed Web of Science ®Google Scholar
• Diaz-Guimaraens B , Dominguez-SantasM, Suarez-ValleAet al. Petechial skin rash associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol.156(7), 820–822 (2020).
   PubMed Web of Science ®Google Scholar
• Zu ZY , JiangMD, XuPPet al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology296(2), e15–e25 (2020).
   PubMed Web of Science ®Google Scholar
• Lippi G , PlebaniM. Laboratory abnormalities in patients with COVID-2019 infection. Clin. Chem. Lab. Med.58(7), 1131–1134 (2020).
   PubMed Web of Science ®Google Scholar
• Bai Y , YaoL, WeiTet al. Presumed asymptomatic carrier transmission of COVID-19. JAMA323(14), 1406–1407 (2020).
   PubMed Web of Science ®Google Scholar
• Sallard E , LescureF-X, YazdanpanahYet al. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res.178, 104791 (2020).
   PubMed Web of Science ®Google Scholar
• Huang C , WangY, LiXet al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet395(10223), 497–506 (2020).
   PubMed Web of Science ®Google Scholar
• Tillett RL , SevinskyJR, HartleyPDet al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect. Dis.21(1), 52–58 (2021).
   PubMed Web of Science ®Google Scholar
• Iwasaki A . What reinfections mean for COVID-19. Lancet Infect. Dis.21(1), 3–5 (2021).
   PubMed Web of Science ®Google Scholar
• Farjadian F , GhasemiA, GohariO, RoointanA, KarimiM, HamblinMR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine14(1), 93–126 (2019).
   PubMed Web of Science ®Google Scholar
• Farjadian F , RoointanA, Mohammadi-SamaniS, HosseiniM. Mesoporous silica nanoparticles: synthesis, pharmaceutical applications, biodistribution, and biosafety assessment. Chem. Eng. J.359, 684–705 (2019).
   Web of Science ®Google Scholar
• Farjadian F , MoghoofeiM, MirkianiSet al. Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: set the bugs to work? Biotechnol. Adv. 36(4), 968–985 (2018).
   PubMed Web of Science ®Google Scholar
• Ahmadi S , RabieeN, BagherzadehMet al. Stimulus-responsive sequential release systems for drug and gene delivery. Nano Today34, 100914 (2020).
   PubMed Web of Science ®Google Scholar
• Entezar-Almahdi E , Mohammadi-SamaniS, TayebiL, FarjadianF. Recent advances in designing 5-fluorouracil delivery systems: a stepping stone in the safe treatment of colorectal cancer. Int. J. Nanomed.15, 5445–5458 (2020).
   PubMed Web of Science ®Google Scholar
• Akbarian M , YousefiR, FarjadianF, UverskyVN. Insulin fibrillation: toward strategies for attenuating the process. Chem. Commun.56(77), 11354–11373 (2020).
   PubMed Web of Science ®Google Scholar
• Hosseini M , FarjadianF, MakhloufASH. Smart stimuli-responsive nano-sized hosts for drug delivery. In:Industrial Applications for Intelligent Polymers and Coatings. HosseiniM, MakhloufASH (Eds). Springer, Cham, Switzerland, doi:https://doi.org/10.1007/978-3-319-26893-4_1 (2016).
   Google Scholar
• Du Y-X , ChenX-P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther.108(2), 242–247 (2020).
   PubMed Web of Science ®Google Scholar
• Furuta Y , GowenBB, TakahashiK, ShirakiK, SmeeDF, BarnardDL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res.100(2), 446–454 (2013).
   PubMed Web of Science ®Google Scholar
• Oestereich L , LüdtkeA, WurrS, RiegerT, Muñoz-FontelaC, GüntherS. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res.105, 17–21 (2014).
   PubMed Web of Science ®Google Scholar
• Padhi AK , DandapatJ, UverskyVN, TripathiT. Structural proteomics-driven targeted design of favipiravir-binding site in the RdRp of SARS-CoV-2 unravels susceptible hotspots and resistance mutations. Preprints doi:10.1002/1873-3468.14182 (2021) ( Epub ahead of print).
   Google Scholar
• Cai Q , YangM, LiuDet al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering6(10), 1192–1198 (2020).
   Web of Science ®Google Scholar
• Chen C , HuangJ, ChengZet al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv doi:https://doi.org/10.1101/2020.03.17.20037432 (2020) ( Epub ahead of print).
   Google Scholar
• Corbett AH , LimML, KashubaAD. Kaletra (lopinavir/ritonavir). Ann. Pharmacother.36(7–8), 1193–1203 (2002).
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS , GoaKL. Lopinavir/ritonavir. Drugs63(8), 769–802 (2003).
   PubMed Web of Science ®Google Scholar
• Cao B , WangY, WenDet al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med.382, 1788–1799 (2020).
   Web of Science ®Google Scholar
• Agostini ML , AndresEL, SimsACet al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio9(2), e00221–18 (2018).
   PubMed Web of Science ®Google Scholar
• De Wit E , FeldmannF, CroninJet al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl Acad. Sci. USA117(12), 6771–6776 (2020).
   PubMed Web of Science ®Google Scholar
• Joe P , AshutoshMS, GajapathirajuC, AsmitaG. The journey of remdesivir: from Ebola to COVID-19. Drugs Context9, 4–14 (2020).
   Google Scholar
• Savarino A , DiTrani L, DonatelliI, CaudaR, CassoneA. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis.6(2), 67–69 (2006).
   PubMed Web of Science ®Google Scholar
• Padhi AK , ShuklaR, SaudagarP, TripathiT. High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance. iScience24(1), 101992 (2021).
   PubMed Web of Science ®Google Scholar
• Grein J , OhmagariN, ShinDet al. Compassionate use of remdesivir for patients with severe COVID-19. N. Engl. J. Med.382(24), 2327–2336 (2020).
   PubMed Web of Science ®Google Scholar
• Beigel JH , TomashekKM, DoddLEet al. Remdesivir for the treatment of COVID-19 – preliminary report. N. Engl. J. Med.383(19), 1813–1836 (2020).
   PubMed Web of Science ®Google Scholar
• Goldman JD , LyeDC, HuiDSet al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N. Engl. J. Med.383(19), 1827–1837 (2020).
   PubMed Web of Science ®Google Scholar
• Proskurnina EV , IzmailovDY, SozarukovaMM, ZhuravlevaTA, LenevaIA, PoromovAA. Antioxidant potential of antiviral drug umifenovir. Molecules25(7), 1577 (2020).
   PubMed Web of Science ®Google Scholar
• Villalaín J . Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes. J. Phys. Chem. B.114(25), 8544–8554 (2010).
   PubMed Web of Science ®Google Scholar
• Lian N , XieH, LinS, HuangJ, ZhaoJ, LinQ. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin. Microbiol. Infect.26(7), 917–921 (2020).
   PubMed Web of Science ®Google Scholar
• Zhu Z , LuZ, XuTet al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J. Infect.81(1), e21–e23 (2020).
   PubMed Web of Science ®Google Scholar
• Gautret P , LagierJ-C, ParolaPet al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents56(1), 105949 (2020).
   PubMed Web of Science ®Google Scholar
• Borba MGS , ValFFA, SampaioVSet al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw.3(4), e208857 (2020).
   Google Scholar
• Arshad S , KilgoreP, ChaudhryZSet al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int. J. Infect. Dis.97, 396–403 (2020).
   PubMed Web of Science ®Google Scholar
• Padhi AK , SealA, KhanJM, AhamedM, TripathiT. Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: insights from atomistic simulations. Eur. J. Pharmacol.894, 173836 (2021).
   PubMed Web of Science ®Google Scholar
• Liu J , CaoR, XuMet al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov.6(1), 1–4 (2020).
   PubMed Web of Science ®Google Scholar
• Kouznetsova J , SunW, Martínez-RomeroCet al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg. Microbes Infect.3(1), 1–7 (2014).
   PubMed Web of Science ®Google Scholar
• Andreani J , LeBideau M, DuflotIet al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb. Pathog.145, 104228 (2020).
   PubMed Web of Science ®Google Scholar
• Kanoh S , RubinBK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev.23(3), 590–615 (2010).
   PubMed Web of Science ®Google Scholar
• Lee N , WongC-K, ChanMCet al. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial. Antiviral Res.144, 48–56 (2017).
   PubMed Web of Science ®Google Scholar
• Lim J , JeonS, ShinH-Yet al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J. Korean Med. Sci.35(6), e79 (2020).
   PubMed Web of Science ®Google Scholar
• Rochwerg B , AgarwalA, ZengLet al. Remdesivir for severe COVID-19: a clinical practice guideline. BMJ370, m2924 (2020).
   PubMedGoogle Scholar
• Damle B , VourvahisM, WangE, LeaneyJ, CorriganB. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin. Pharmacol. Ther.108(2), 201–211 (2020).
   PubMed Web of Science ®Google Scholar
• Cortegiani A , IngogliaG, IppolitoM, GiarratanoA, EinavS. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care57, 279–283 (2020).
   PubMed Web of Science ®Google Scholar
• Wang K , ChenW, ZhangZet al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target. Ther.5(1), 1–10 (2020).
   PubMed Web of Science ®Google Scholar
• Kaptein SJ , JacobsS, LangendriesLet al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Natl Acad. Sci. USA117(43), 26955–26965 (2020).
   PubMed Web of Science ®Google Scholar
• Sayad B , SobhaniM, KhodarahmiR. Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered/approved clinical trial?Arch. Med. Res.51(6), 577–581 (2020).
   PubMed Web of Science ®Google Scholar
• Vankadari N . Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein?Int. J. Antimicrob. Agents56(2), 105998 (2020).
   PubMed Web of Science ®Google Scholar
• Cortegiani A , IngogliaG, IppolitoM, GiarratanoA, EinavS. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care57, 279–283 (2020).
   PubMed Web of Science ®Google Scholar
• Sultana J , CutroneoPM, CrisafulliS, PuglisiG, CaramoriG, TrifiròG. Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf.43(8), 691–698 (2020).
   PubMed Web of Science ®Google Scholar
• Anderson VR , CurranMP. Nitazoxanide. Drugs67(13), 1947–1967 (2007).
   PubMed Web of Science ®Google Scholar
• Rossignol J-F . Nitazoxanide, a new drug candidate for the treatment of Middle East Respiratory Syndrome coronavirus. J. Infect. Public Health9(3), 227–230 (2016).
   PubMed Web of Science ®Google Scholar
• Kelleni M . Nitazoxanide/azithromycin combination for COVID-19: a suggested new protocol for COVID-19 early management. Pharmacol. Res.157, 104874 (2020).
   PubMed Web of Science ®Google Scholar
• Yavuz S , ÜnalS. Antiviral treatment of COVID-19. Turk. J. Med. Sci.50(SI-1), 611–619 (2020).
   PubMedGoogle Scholar
• Calderón JM , ZerónHM, PadmanabhanS. Treatment with hydroxychloroquine vs hydroxychloroquine + nitazoxanide in COVID-19 patients with risk factors for poor prognosis: a structured summary of a study protocol for a randomised controlled trial. Trials21(1), 1–3 (2020).
   PubMedGoogle Scholar
• Tay M , FraserJE, ChanWet al. Nuclear localization of dengue virus (DENV) 1–4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor ivermectin. Antiviral Res.99(3), 301–306 (2013).
   PubMed Web of Science ®Google Scholar
• Wagstaff KM , SivakumaranH, HeatonSM, HarrichD, JansDA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem. J.443(3), 851–856 (2012).
   PubMed Web of Science ®Google Scholar
• Varghese FS , KaukinenP, GläskerSet al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res.126, 117–124 (2016).
   PubMed Web of Science ®Google Scholar
• Barrows NJ , CamposRK, PowellSTet al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe20(2), 259–270 (2016).
   PubMed Web of Science ®Google Scholar
• Caly L , DruceJD, CattonMG, JansDA, WagstaffKM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res.178, 104787 (2020).
   PubMed Web of Science ®Google Scholar
• Guzzo CA , FurtekCI, PorrasAGet al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol.42(10), 1122–1133 (2002).
   PubMed Web of Science ®Google Scholar
• Menez C , SutraJ-F, PrichardR, LespineA. Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA (A) channel activity. PLoS Negl. Trop. Dis.6(11), e1883 (2012).
   PubMed Web of Science ®Google Scholar
• Lepist E-I , PhanTK, RoyAet al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob. Agents Chemother.56(10), 5409–5413 (2012).
   PubMed Web of Science ®Google Scholar
• Drewe J , GutmannH, FrickerG, TörökM, BeglingerC, HuwylerJ. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol.57(10), 1147–1152 (1999).
   PubMed Web of Science ®Google Scholar
• Patrì A , FabbrociniG. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and treatment?J. Am. Acad. Dermatol.82(6), e221 (2020).
   PubMed Web of Science ®Google Scholar
• Nouchi A , MonselG, Lafon-DesmursBet al. Epstein–Barr virus-related acute genital ulcer successfully treated with colchicine. Acta Derm. Vener.98(1–2), 134–135 (2018).
   PubMed Web of Science ®Google Scholar
• Arrieta O , Rodriguez-DiazJL, Rosas-CamargoVet al. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer107(8), 1852–1858 (2006).
   PubMed Web of Science ®Google Scholar
• Floreani A , LobelloS, BrunettoM, AneloniV, ChiaramonteM. Colchicine in chronic hepatitis B: a pilot study. Aliment. Pharmacol. Ther.12(7), 653–656 (1998).
   PubMed Web of Science ®Google Scholar
• Boulis NM , WillmarthNE, SongDK, FeldmanEL, ImperialeMJ. Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. J. Neurosurg.52(2), 381–387 (2003).
   Google Scholar
• Bosem M , HarrisR, AthertonS. Optic nerve involvement in viral spread in herpes simplex virus type 1 retinitis. Invest. Ophthalmol. Vis. Sci.31(9), 1683–1689 (1990).
   PubMed Web of Science ®Google Scholar
• Leung YY , HuiLLY, KrausVB. Colchicine – update on mechanisms of action and therapeutic uses. Semin. Arthritis Rheum.45(3), 341–350 (2015).
   PubMed Web of Science ®Google Scholar
• Akalin E , AzziY, BartashRet al. COVID-19 and kidney transplantation. N. Engl. J. Med.382(25), 2475–2477 (2020).
   PubMedGoogle Scholar
• Mehta P , McauleyDF, BrownMet al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet395(10229), 1033 (2020).
   PubMed Web of Science ®Google Scholar
• Kuba K , ImaiY, RaoSet al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat. Med.11(8), 875–879 (2005).
   PubMed Web of Science ®Google Scholar
• Becatti M , EmmiG, SilvestriEet al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease. Circulation133(3), 302–311 (2016).
   PubMed Web of Science ®Google Scholar
• Tardif J-C , KouzS, WatersDDet al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med.381(26), 2497–2505 (2019).
   PubMed Web of Science ®Google Scholar
• Toniati P , PivaS, CattaliniMet al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun. Rev.19(7), 102568 (2020).
   PubMed Web of Science ®Google Scholar
• Piantoni S , ColomboE, AiròPet al. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al. Clin. Rheumatol.39(8), 2489–2490 (2020).
   PubMed Web of Science ®Google Scholar
• Cure MC , KucukA, CureE. Colchicine may not be effective in COVID-19 infection; it may even be harmful?Clin. Rheumatol.39(7), 2101–2102 (2020).
   PubMed Web of Science ®Google Scholar
• Fang L , KarakiulakisG, RothM. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?Lancet Respir. Med.8(4), e21 (2020).
   PubMed Web of Science ®Google Scholar
• Ip A , ParikhK, ParrilloJEet al. Hypertension and renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. medRxiv doi:https://doi.org/10.1101/2020.04.24.20077388 (2020) ( Epub ahead of print).
   Google Scholar
• Moore N , CarletonB, BlinP, Bosco-LevyP, DrozC. Does ibuprofen worsen COVID-19?Drug Saf.43, 611–614 (2020).
   PubMed Web of Science ®Google Scholar
• Trifirò G , CrisafulliS, AndòG, RacagniG, DragoF. Should patients receiving ACE inhibitors or angiotensin receptor blockers be switched to other antihypertensive drugs to prevent or improve prognosis of novel coronavirus disease 2019 (COVID-19)?Drug Saf.43, 507–509 (2020).
   PubMed Web of Science ®Google Scholar
• Kuster GM , PfisterO, BurkardTet al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? Eur. Heart J. 41(19), 1801–1803 (2020).
   PubMed Web of Science ®Google Scholar
• Capuano A , ScaglioneF, BerrinoLet al. Official statement of the section of clinical pharmacology of Italian Society of Pharmacology on non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections. Pharm. Adv.2(10), 36118 (2020).
   Google Scholar
• Castro VM , RossRA, McbrideSM, PerlisRH. Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. medRxiv doi:https://doi.org/10.1101/2020.04.11.20061994 (2020) ( Epub ahead of print).
   PubMedGoogle Scholar
• Dilly S , FotsoFotso AL, LejalNet al. From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus. J. Med. Chem.61(16), 7202–7217 (2018).
   PubMed Web of Science ®Google Scholar
• Lejal N , TruchetS, BechorEet al. Turning off NADPH oxidase-2 by impeding p67phox activation in infected mouse macrophages reduced viral entry and inflammation. Biochim. Biophys. Acta. Gen. Sub.1862(6), 1263–1275 (2018).
   PubMed Web of Science ®Google Scholar
• Terrier O , DillyS, PizzornoM-Aet al. Broad-spectrum antiviral activity of naproxen: from influenza A to SARS-CoV-2 coronavirus. bioRxiv doi:https://doi.org/10.1101/2020.04.30.069922 (2020) ( Epub ahead of print).
   PubMedGoogle Scholar
• Lejal N , TarusB, BouguyonEet al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob. Agents Chemother.57(5), 2231–2242 (2013).
   PubMed Web of Science ®Google Scholar
• Berk M , MalhiGS, GrayLJ, DeanOM. The promise of N-acetylcysteine in neuropsychiatry. Trend. Pharmacol. Sci.34(3), 167–177 (2013).
   PubMed Web of Science ®Google Scholar
• De Flora S , BalanskyR, LaMaestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J.34(10), 13185–13193 (2020).
   PubMed Web of Science ®Google Scholar
• Aslamkhan AG , HanY-H, YangX-P, ZalupsRK, PritchardJB. Human renal organic anion transporter 1-dependent uptake and toxicity of mercuric-thiol conjugates in Madin-Darby canine kidney cells. Mol. Pharmacol.63(3), 590–596 (2003).
   PubMed Web of Science ®Google Scholar
• Nasi A , McardleS, GaudernackGet al. Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. Toxicol. Rep.7, 768–771 (2020).
   PubMed Web of Science ®Google Scholar
• Polonikov A . Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect. Dis.6(7), 1558–1562 (2020).
   PubMed Web of Science ®Google Scholar
• Gulati K , RaiN, ChaudharyS, RayA. Nutraceuticals in respiratory disorders. In: Nutraceuticals. GuptaRC (Ed.). Elsevier, 75–86 (2016).
   Google Scholar
• Pospıšilová M , PolášekM, JoklV. Determination of ambroxol or bromhexine in pharmaceuticals by capillary isotachophoresis. J. Pharmaceut. Biomed. Anal.24(3), 421–428 (2001).
   PubMed Web of Science ®Google Scholar
• Tripathi K . Essentials of medical pharmacology. JP Medical Ltd (2013).
   Google Scholar
• Brogan T , RyleyH, HuttH, NealeL. The effect of bromhexine on sputum from patients with chronic bronchitis and asthma. Br. J. Dis. Chest68, 28–34 (1974).
   PubMedGoogle Scholar
• Christensen F , KjerJ, RyskjaerS, Arseth-HansenP. Bromhexine in chronic bronchitis. Br. Med. J.4(5727), 117 (1970).
   PubMedGoogle Scholar
• Deretic V , TimminsGS. Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert Opin. Drug Metab. Toxicol.15(3), 213–218 (2019).
   PubMed Web of Science ®Google Scholar
• Shen LW , MaoHJ, WuYL, TanakaY, ZhangW. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections. Biochimie142, 1–10 (2017).
   PubMed Web of Science ®Google Scholar
• Maggio R , CorsiniGU. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol. Res.157, 104837 (2020).
   PubMed Web of Science ®Google Scholar
• Tay MZ , PohCM, RéniaL, MacaryPA, NgLF. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol.20, 363–374 (2020).
   PubMed Web of Science ®Google Scholar
• Mcgonagle D , O'donnellJS, SharifK, EmeryP, BridgewoodC. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol.2(7), e437–e445 (2020).
   PubMedGoogle Scholar
• King A , VailA, O'learyCet al. Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatol.2(7), e437–e445 (2020).
   PubMedGoogle Scholar
• Owji H , NegahdaripourM, HajighahramaniN. Immunotherapeutic approaches to curtail COVID-19. Int. Immunpharmacol.88, 106924 (2020).
   PubMed Web of Science ®Google Scholar
• Huet T , BeaussierH, VoisinOet al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol.2(7), e393–e400 (2020).
   PubMedGoogle Scholar
• Aouba A , BaldolliA, GeffrayLet al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann. Rheum. Dis.79(10), 1381–1382 (2020).
   PubMed Web of Science ®Google Scholar
• Cavalli G , DeLuca G, CampochiaroCet al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol.2(6), e325–e331 (2020).
   PubMedGoogle Scholar
• Ji P , ChenJ, GoldingAet al. Immunomodulatory therapeutic proteins in COVID-19: current clinical development and clinical pharmacology considerations. J. Clin. Pharmacol.60(10), 1275–1293 (2020).
   PubMed Web of Science ®Google Scholar
• Österlund P , VeckmanV, SirénJet al. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J. Virol.79(15), 9608–9617 (2005).
   PubMed Web of Science ®Google Scholar
• Lin F-C , YoungHA. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev.25(4), 369–376 (2014).
   PubMed Web of Science ®Google Scholar
• Dastan F , NadjiSA, SaffaeiAet al. Subcutaneous administration of interferon beta-1a for COVID-19: a non-controlled prospective trial. Int. Immunopharmacol.85, 106688 (2020).
   PubMed Web of Science ®Google Scholar
• Bagheri A , MoezziSMI, MosaddeghiPet al. Interferon-inducer antivirals: potential candidates to combat COVID-19. Int. Immunopharmacol.91, 107245 (2021).
   PubMed Web of Science ®Google Scholar
• Pérez-Olmeda M , NúñezM, RomeroMet al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS17(7), 1023–1028 (2003).
   PubMed Web of Science ®Google Scholar
• Sokal EM , ConjeevaramHS, RobertsEAet al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology114(5), 988–995 (1998).
   PubMed Web of Science ®Google Scholar
• Jakimovski D , KolbC, RamanathanM, ZivadinovR, Weinstock-GuttmanB. Interferon β for multiple sclerosis. Cold Spring Harb. Perspect. Med.8(11), a032003 (2018).
   PubMed Web of Science ®Google Scholar
• Quesada JR , ReubenJ, ManningJT, HershEM, GuttermanJU. Alpha interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med.310(1), 15–18 (1984).
   PubMed Web of Science ®Google Scholar
• Wheatley K , IvesN, EggermontAet al. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J. Clin. Oncol.25(Suppl. 18), 8526–8526 (2007).
   Google Scholar
• Bunn PA Jr , IhdeDC, FoonKA. The role of recombinant interferon alfa-2a in the therapy of cutaneous t-cell lymphomas. Cancer57(S8), 1689–1695 (1986).
   PubMedGoogle Scholar
• Hung IF-N , LungK-C, TsoEY-Ket al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet395(10238), 1695–1704 (2020).
   PubMed Web of Science ®Google Scholar
• Isidori A , ArnaldiG, BoscaroMet al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J. Endocrinol. Invest.43(8), 1141–1147 (2020).
   PubMed Web of Science ®Google Scholar
• Shi Y , WangY, ShaoCet al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ.27(5), 1451–1454 (2020).
   PubMed Web of Science ®Google Scholar
• Rassy D , BárcenaB, Pérez-OsorioINet al. Intranasal methylprednisolone effectively reduces neuroinflammation in mice with experimental autoimmune encephalitis. J. Neuropathol. Exp. Neur.79(2), 226–237 (2020).
   PubMed Web of Science ®Google Scholar
• Zha L , LiS, PanLet al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med. J. Aust.212(9), 416–420 (2020).
   PubMed Web of Science ®Google Scholar
• Ho C-M , HoS-T, WangJ-J, TsaiS-K, ChaiC-Y. Dexamethasone has a central antiemetic mechanism in decerebrated cats. Anesth. Analg.99(3), 734–739 (2004).
   PubMed Web of Science ®Google Scholar
• Giles AJ , HutchinsonM-KN, SonnemannHMet al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J. Immunother. Cancer6(1), 1–13 (2018).
   PubMedGoogle Scholar
• Theoharides T , ContiP. Dexamethasone for COVID-19? Not so fast. J. Biol. Regul. Homeost. Agents34(3), 10.23812 (2020).
   Google Scholar
• Johnson RM , VinetzJM. Dexamethasone in the management of COVID-19. Br. Med. J.370, m2648 (2020).
   PubMedGoogle Scholar
• Horby P , LimWS, EmbersonJRet al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N. Engl. J. Med.384(8), 693–704 (2020).
   PubMed Web of Science ®Google Scholar
• Gallagher C . The mechanism of action of hydrocortisone on mitochondrial metabolism. Biochem. J.74(1), 38–43 (1960).
   PubMedGoogle Scholar
• Pudrith C , KimYH, MartinDet al. Effect of topical treatment of various glucocorticoids on lipopolysaccharide induced otitis media with effusion in chinchilla. Int. J. Pediatr. Otorhinolaryngol.74(11), 1273–1275 (2010).
   PubMed Web of Science ®Google Scholar
• Prete A , TaylorAE, BancosIet al. Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery. J. Clin. Endocrinol. Metab.105(7), 2262–2274 (2020).
   PubMed Web of Science ®Google Scholar
• Almeida MQ , MendoncaBB. Adrenal insufficiency and glucocorticoid use during the COVID-19 pandemic. Clinics75, e2022 (2020).
   PubMed Web of Science ®Google Scholar
• Reynolds NA , PerryCM, KeatingGM. Budesonide/formoterol. Drugs64(4), 431–441 (2004).
   PubMed Web of Science ®Google Scholar
• Health NIO . Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO work shop report (1995).
   Google Scholar
• Halpin DM , SinghD, HadfieldRM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur. Respir. J.55(5), 2001009 (2020).
   PubMed Web of Science ®Google Scholar
• Wu Z , McgooganJM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA323(13), 1239–1242 (2020).
   PubMed Web of Science ®Google Scholar
• Szafranski W , CukierA, RamirezAet al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J.21(1), 74–81 (2003).
   PubMed Web of Science ®Google Scholar
• Yang M , ZhangY, ChenH, LinJ, ZengJ, XuZ. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis. Infection47(3), 377–385 (2019).
   PubMed Web of Science ®Google Scholar
• Lipworth B , KuoCR, LipworthS, ChanR. Inhaled corticosteroids and COVID-19. Am. J. Respir. Crit. Care Med.202(6), 899–900 (2020).
   PubMed Web of Science ®Google Scholar
• Ingwersen J , AktasO, KueryP, KieseierB, BoykoA, HartungH-P. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin. Immunol.142(1), 15–24 (2012).
   PubMed Web of Science ®Google Scholar
• Sanders JM , MonogueML, JodlowskiTZ, CutrellJB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA323(18), 1824–1836 (2020).
   PubMed Web of Science ®Google Scholar
• Fox RI , HerrmannML, FrangouCGet al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol.93(3), 198–208 (1999).
   PubMed Web of Science ®Google Scholar
• Xiao K , HouF, HuangX, LiB, QianZR, XieL. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. Stem Cell Res. Ther.11(1), 305 (2020).
   PubMed Web of Science ®Google Scholar
• Amirshahrokhi K . Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice. Int. Immunopharmacol.17(2), 210–215 (2013).
   PubMed Web of Science ®Google Scholar
• Dong X , LiX, LiM, ChenM, FanQ, WeiW. Antiinflammation and antioxidant effects of thalidomide on pulmonary fibrosis in mice and human lung fibroblasts. Inflammation40(6), 1836–1846 (2017).
   PubMed Web of Science ®Google Scholar
• Dastan F , TabarsiP, MarjaniMet al. Thalidomide against coronavirus disease 2019 (COVID-19): a medicine with a thousand faces. Iran J. Pharmaceut. Res.19(1), 1–2 (2020).
   Web of Science ®Google Scholar
• Zhu H , ShiX, JuD, HuangH, WeiW, DongX. Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice. Inflammation37(6), 2091–2098 (2014).
   PubMed Web of Science ®Google Scholar
• Peng H , GongT, HuangXet al. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. Stem Cell Res. Ther.11(1), 1–6 (2020).
   PubMed Web of Science ®Google Scholar
• Sebba A . Tocilizumab: the first interleukin-6-receptor inhibitor. Am. J. Health-Syst. Pharm.65(15), 1413–1418 (2008).
   PubMed Web of Science ®Google Scholar
• Khiali S , KhaniE, Entezari-MalekiT. A comprehensive review of tocilizumab in COVID-19 acute respiratory distress syndrome. J. Clin. Pharmacol.60(9), 1131–1146 (2020).
   PubMed Web of Science ®Google Scholar
• Alzghari SK , AcuñaVS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J. Clin. Virol.127, 104380 (2020).
   PubMed Web of Science ®Google Scholar
• Jain S , SharmaSK. Rational use of tocilizumab in COVID-19. Ann. Rheum. Dis. Doi:10.1136/annrheumdis-2020-218519. (2020) ( Epub ahead of print).
   Google Scholar
• Fajgenbaum DC , JuneCH. Cytokine storm. N. Engl. J. Med.383(23), 2255–2273 (2020).
   PubMed Web of Science ®Google Scholar
• Fu B , XuX, WeiH. Why tocilizumab could be an effective treatment for severe COVID-19?J. Transl. Med.18(1), 164 (2020).
   PubMed Web of Science ®Google Scholar
• Xu X , HanM, LiTet al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci.117(20), 10970–10975 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang S , LiL, ShenA, ChenY, QiZ. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin. Drug Invest.40(6), 511–518 (2020).
   PubMed Web of Science ®Google Scholar
• Samaee H , MohsenzadeganM, AlaS, MaroufiSS, MoradimajdP. Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease. Int. Immunopharmacol.89, 107018 (2020).
   PubMed Web of Science ®Google Scholar
• Scott LJ . Sarilumab: first global approval. Drugs77(6), 705–712 (2017).
   PubMed Web of Science ®Google Scholar
• Della-Torre E , CampochiaroC, CavalliGet al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann. Rheum. Dis.79(10), 1277–1285 (2020).
   PubMed Web of Science ®Google Scholar
• Crisafulli S , IsgròV, LaCorte L, AtzeniF, TrifiròG. Potential role of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: rationale, clinical evidence and risks. BioDrugs34(4), 415–422 (2020).
   PubMed Web of Science ®Google Scholar
• Hu S , LiangS, GuoHet al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J. Biolog. Chem.288(38), 27059–27067 (2013).
   PubMed Web of Science ®Google Scholar
• Wang D , ChenW, LiHet al. Folate-receptor mediated pH/reduction-responsive biomimetic nanoparticles for dually activated multi-stage anticancer drug delivery. Int. J. Pharmaceut.585, 119456 (2020).
   PubMed Web of Science ®Google Scholar
• Rizk JG , Kalantar-ZadehK, MehraMR, LavieCJ, RizkY, ForthalDN. Pharmaco-immunomodulatory therapy in COVID-19. Drugs80, 1267–1292 (2020).
   PubMed Web of Science ®Google Scholar
• Tursi A , AngaranoG, MonnoLet al. COVID-19 infection in Crohn's disease under treatment with adalimumab. Gut69(7), 1364–1365 (2020).
   PubMed Web of Science ®Google Scholar
• Rosa SGV , SantosWC. Clinical trials on drug repositioning for COVID-19 treatment. Rev. Panam. Salud. Pública.44, e40 (2020).
   PubMed Web of Science ®Google Scholar
• Scavone C , BruscoS, BertiniMet al. Current pharmacological treatments for COVID-19: what's next? Br. J. Pharmacol. 177(21), 4813–4824 (2020).
   PubMed Web of Science ®Google Scholar
• Medford A , MillarA. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?Thorax61(7), 621–626 (2006).
   PubMed Web of Science ®Google Scholar
• Ellis LM . Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Presented at: Semin. Oncol.33, S1–S7 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JW , SicreDe Fontbrune F, WongLee Lee Let al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood133(6), 530–539 (2019).
   PubMed Web of Science ®Google Scholar
• Gavriilaki E , BrodskyRA. Severe COVID-19 infection and thrombotic microangiopathy: success doesn't come easily. Br. J. Haematol.189(6), e227–e230 (2020).
   PubMed Web of Science ®Google Scholar
• Java A , ApicelliAJ, LiszewskiMKet al. The complement system in COVID-19: friend and foe? JCI Insight 5(15), e140711 (2020).
   PubMed Web of Science ®Google Scholar
• Jodele S , KöhlJ. Tackling COVID-19 infection through complement-targeted immunotherapy. Br. J. Pharmacol.178(14), 2832–2848 (2020).
   PubMed Web of Science ®Google Scholar
• Smith K , PaceA, OrtizS, KazaniS, RottinghausS. A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of intravenously administered ravulizumab compared with best supportive care in patients with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome: a structured summary of a study protocol for a randomised controlled trial. Trials21(1), 1–4 (2020).
   PubMed Web of Science ®Google Scholar
• Crotti C , AgapeE, BeccioliniA, BiggioggeroM, FavalliEG. Targeting granulocyte-monocyte colony-stimulating factor signaling in rheumatoid arthritis: future prospects. Drugs79(16), 1741–1755 (2019).
   PubMed Web of Science ®Google Scholar
• Bonaventura A , VecchiéA, WangTSet al. Targeting GM-CSF in COVID-19 pneumonia: rationale and strategies. Front. Immunol.11, 1625 (2020).
   PubMed Web of Science ®Google Scholar
• Lang FM , LeeKM-C, TeijaroJR, BecherB, HamiltonJA. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. Nat. Rev. Immunol.20(8), 507–514 (2020).
   PubMed Web of Science ®Google Scholar
• Temesgen Z , AssiM, ShwetaFet al. GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case–control study. Mayo Clin. Proc.95(11), 2382–2394 (2020).
   PubMed Web of Science ®Google Scholar
• Connors JM , LevyJH. COVID-19 and its implications for thrombosis and anticoagulation. Blood J. Am. Soc. Hematol.135(23), 2033–2040 (2020).
   Google Scholar
• Subramaniam S , JurkK, HobohmLet al. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood129(16), 2291–2302 (2017).
   PubMed Web of Science ®Google Scholar
• Iba T , LevyJ. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J. Thromb. Haemost.16(2), 231–241 (2018).
   PubMed Web of Science ®Google Scholar
• Iba T , LevyJ. Derangement of the endothelial glycocalyx in sepsis. J. Thromb. Haemost.17(2), 283–294 (2019).
   PubMed Web of Science ®Google Scholar
• Hirsh J , AnandSS, HalperinJL, FusterV. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler. Thromb. Vasc. Biol.21(7), 1094–1096 (2001).
   PubMed Web of Science ®Google Scholar
• Marone EM , RinaldiLF. Upsurge of deep venous thrombosis in patients affected by COVID-19: preliminary data and possible explanations. J. Vasc. Surg. Venous Lymphat. Disord.8(4), 694–695 (2020).
   PubMedGoogle Scholar
• Demelo-Rodríguez P , Cervilla-MuñozE, Ordieres-OrtegaLet al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb. Res.192, 23–26 (2020).
   PubMed Web of Science ®Google Scholar
• Chen S , ZhangD, ZhengT, YuY, JiangJ. DVT incidence and risk factors in critically ill patients with COVID-19. J. Thromb.51(1), 33–39 (2020).
   Google Scholar
• Liu J , LiJ, ArnoldK, PawlinskiR, KeyNS. Using heparin molecules to manage COVID-2019. Res. Pract. Thromb. Haemost.4(4), 518–523 (2020).
   PubMed Web of Science ®Google Scholar
• Thachil J . The versatile heparin in COVID-19. J. Thromb. Haemost.18(5), 1020–1022 (2020).
   PubMed Web of Science ®Google Scholar
• Iba T , HashiguchiN, NagaokaI, TabeY, KadotaK, SatoK. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med. Exp.3(1), 36 (2015).
   PubMedGoogle Scholar
• Samama MM . The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thromb. Res.127(6), 497–504 (2011).
   PubMed Web of Science ®Google Scholar
• Di Tano G , MoschiniL, LoffiM, TestaS, DanziGB. Late pulmonary embolism after COVID-19 pneumonia despite adequate rivaroxaban treatment. Eur. J. Case Rep. Intern. Med.7(7), 001790 (2020).
   PubMedGoogle Scholar
• Cattaneo M , BertinatoEM, BirocchiSet al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb. Haemost. 120(8), 1230–1232 (2020).
   PubMed Web of Science ®Google Scholar
• Pannucci CJ , FlemingKI, HoloydaK, MoultonL, PrazakAM, VargheseTKJr. Enoxaparin 40 mg per day is inadequate for venous thromboembolism prophylaxis after thoracic surgical procedure. Ann. Thorac. Surg.106(2), 404–411 (2018).
   PubMed Web of Science ®Google Scholar
• Brotons C , BenamouzigR, FilipiakKJ, LimmrothV, BorghiC. A systematic review of aspirin in primary prevention: is it time for a new approach?Am. J. Cardiovasc. Drugs15(2), 113–133 (2015).
   PubMed Web of Science ®Google Scholar
• Mekaj YH , DaciFT, MekajAY. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther. Clin. Risk Manag.11, 1449 (2015).
   PubMed Web of Science ®Google Scholar
• Mohamed-Hussein AA , AlyKM, IbrahimM. Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy?Med. Hypotheses144, 109975 (2020).
   PubMed Web of Science ®Google Scholar
• Eisenhut M , ShinJI. Pathways in the pathophysiology of coronavirus 19 lung disease accessible to prevention and treatment. Front. Physiol.11, 872 (2020).
   PubMed Web of Science ®Google Scholar
• Erlich JM , TalmorDS, Cartin-CebaR, GajicO, KorDJ. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest139(2), 289–295 (2011).
   PubMed Web of Science ®Google Scholar
• Kor DJ , ErlichJ, GongMNet al. Association of pre-hospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit. Care Med.39(11), 2393 (2011).
   PubMed Web of Science ®Google Scholar
• O'neal HR Jr , KoyamaT, KoehlerEAet al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit. Care Med.39(6), 1343–1350 (2011).
   PubMed Web of Science ®Google Scholar
• Davies JT , DelfinoSF, FeinbergCEet al. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights9, LPI. S37450 (2016).
   Google Scholar
• Stancu C , SimaA. Statins: mechanism of action and effects. J. Cell Mol. Med.5(4), 378–387 (2001).
   PubMed Web of Science ®Google Scholar
• Olszewska-Parasiewicz J , SzarpakŁ, RogulaSet al. Statins in COVID-19 therapy. Life11(6), 565 (2021).
   PubMedGoogle Scholar
• Rodrigues-Diez RR , Tejera-MuñozA, Marquez-ExpositoLet al. Statins: could an old friend help in the fight against COVID-19? Br. J. Pharmacol. 177(21), 4873–4886 (2020).
   PubMed Web of Science ®Google Scholar
• Plosker GL , Lyseng-WilliamsonKA. Clopidogrel. Drugs67(4), 613–646 (2007).
   PubMed Web of Science ®Google Scholar
• Yu H-R , WeiY-Y, MaJ-G, GengX-Y. Beneficial effects of combined administration of clopidogrel and aspirin on the levels of proinflammatory cytokines, cardiac function, and prognosis in ST-segment elevation myocardial infarction: a comparative study. Medicine97(45), e13010 (2018).
   PubMed Web of Science ®Google Scholar
• Jiang X-L , SamantS, LeskoLJ, SchmidtS. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin. Pharmacokinet.54(2), 147–166 (2015).
   PubMed Web of Science ®Google Scholar
• Bikdeli B , MadhavanMV, JimenezDet al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J. Am. Coll. Cardiol.75(23), 2950–2973 (2020).
   PubMed Web of Science ®Google Scholar
• Ranucci M , BallottaA, DiDedda Uet al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J. Thromb. Haemost.18(7), 1747–1751 (2020).
   PubMed Web of Science ®Google Scholar
• Viecca M , RadovanovicD, ForleoGB, SantusP. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe COVID-19 and hypercoagulability. A case control, proof of concept study. Pharmacol. Res.158, 104950 (2020).
   PubMed Web of Science ®Google Scholar
• Iqbal N , IqbalN. Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract.2014, 9 (2014).
   Google Scholar
• Radford IR . Imatinib. Novartis. Curr. Opin. Investig. Drugs3(3), 492–499 (2002).
   PubMedGoogle Scholar
• Iram H , IramF, HusainA. A review on imatinib: a wonder drug in oncology. Adv. Biomed. Pharm.3, 227–244 (2016).
   Google Scholar
• Morales-Ortega A , Bernal-BelloD, Llarena-BarrosoCet al. Imatinib for COVID-19: a case report. Clin. Immunol.218, 108518 (2020).
   PubMed Web of Science ®Google Scholar
• Rizzo AN , SammaniS, EsquincaAEet al. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol.309(11), L1294–L1304 (2015).
   PubMed Web of Science ®Google Scholar
• Herman SE , MontravetaA, NiemannCUet al. The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin. Cancer Res.23(11), 2831–2841 (2017).
   PubMed Web of Science ®Google Scholar
• Wu M , JiJ-J, ZhongLet al. Thymosin α1 therapy in critically ill patients with COVID-19: a multicenter retrospective cohort study. Int. Immunopharmacol.88, 106873 (2020).
   PubMed Web of Science ®Google Scholar
• Isaac K , MatoAR. Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: a short review on emerging data. Cancer Manag. Res.12, 2079 (2020).
   PubMed Web of Science ®Google Scholar
• Gorham J , MoreauA, CorazzaFet al. Interleukine-6 in critically ill COVID-19 patients: a retrospective analysis. PLoS ONE15(12), e0244628 (2020).
   PubMed Web of Science ®Google Scholar
• Roschewski M , LionakisMS, SharmanJPet al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci. Immunol.5(48), eabd0110 (2020).
   PubMed Web of Science ®Google Scholar
• Mcgee MC , AugustA, HuangW. BTK/ITK dual inhibitors: modulating immunopathology and lymphopenia for COVID-19 therapy. J. Leukoc. Biol.109(1), 49–53 (2021).
   PubMed Web of Science ®Google Scholar
• Talpaz M , KiladjianJ-J. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia35, 1–17 (2021).
   PubMed Web of Science ®Google Scholar
• Mullally A , HoodJ, HarrisonC, MesaR. Fedratinib in myelofibrosis. Blood Adv.4(8), 1792–1800 (2020).
   PubMed Web of Science ®Google Scholar
• Stebbing J , PhelanA, GriffinIet al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis.20(4), 400–402 (2020).
   PubMed Web of Science ®Google Scholar
• Rojas M , RodriguezY, MonsalveDMet al. Convalescent plasma in COVID-19: possible mechanisms of action. Autoimmun. Rev.19(7), 102554 (2020).
   PubMed Web of Science ®Google Scholar
• Roback JD , GuarnerJ. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA323(16), 1561–1562 (2020).
   PubMed Web of Science ®Google Scholar
• Gharbharan A , JordansCC, GeurtsvankesselCet al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat. Commun.12(1), 1–12 (2021).
   PubMed Web of Science ®Google Scholar
• Hegerova L , GooleyTA, SweerusKAet al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood J. Am. Soc. Hematol.136(6), 759–762 (2020).
   Google Scholar
• Tanne JH . COVID-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ368, m1256 (2020).
   PubMed Web of Science ®Google Scholar
• Shao Z , FengY, ZhongLet al. Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: a multicenter retrospective cohort study. Clin. Transl. Immunol.9(10), e1192 (2020).
   PubMed Web of Science ®Google Scholar
• Abdolahi N , KahehE, GolshaRet al. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. Trials21(1), 549 (2020).
   PubMed Web of Science ®Google Scholar
• Cao W , LiuX, BaiTet al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect. Dis.7(3), ofaa102 (2020).
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P , Mohammadi-SamaniS. COVID-19 outbreak: challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. Heart & Lung49(6), 763–773 (2020).
   PubMed Web of Science ®Google Scholar
• Carr AC . A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit. Care24(1), 133 (2020).
   PubMed Web of Science ®Google Scholar
• Liu F , ZhuY, ZhangJ, LiY, PengZ. Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. BMJ Open10(7), e039519 (2020).
   PubMedGoogle Scholar
• Colunga Biancatelli RML , BerrillM, CatravasJD, MarikPE. Quercetin and vitamin c: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19). Front. Immunol.11, 1451 (2020).
   PubMed Web of Science ®Google Scholar
• Cheng RZ . Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?Med. Drug Discov.5, 100028 (2020).
   PubMedGoogle Scholar
• Abobaker A . Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?Eur. J. Clin. Pharmacol.76(11), 1619–1620 (2020).
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P , Mohammadi-SamaniS. Iron chelating agents: promising supportive therapies in severe cases of COVID-19. Trends Pharmaceut. Sci.6(2), 65–66 (2020).
   Google Scholar
• Colafrancesco S , AlessandriC, ContiF, PrioriR. COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome?Autoimmun. Rev.19(7), 102573 (2020).
   PubMed Web of Science ®Google Scholar
• Perricone C , BartoloniE, BursiRet al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol. Res.68(4), 213–224 (2020).
   PubMed Web of Science ®Google Scholar
• Dalamaga M , KarampelaI, MantzorosCS. Commentary: could iron chelators prove to be useful as an adjunct to COVID-19 treatment regimens?Metabolism108, 154260 (2020).
   PubMed Web of Science ®Google Scholar
• Abbas A , MostafaA, YousofE, AliS. Use of iron chelators to reduce the severity of COVID-19. Thromb. Haemost. Res.4(2), 1042 (2020).
   Google Scholar
• Esam Z . A proposed mechanism for the possible therapeutic potential of metformin in COVID-19. Diabetes Res. Clin. Pract.167, 108282 (2020).
   PubMed Web of Science ®Google Scholar
• Sharma S , RayA, SadasivamB. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res. Clin. Pract.164, 108183 (2020).
   PubMed Web of Science ®Google Scholar
• Ursini F , CiaffiJ, LandiniMP, MeliconiR. COVID-19 and diabetes: is metformin a friend or foe?Diabetes Res. Clin. Pract.164, 108167 (2020).
   PubMed Web of Science ®Google Scholar
• Scheen AJ . Metformin and COVID-19: from cellular mechanisms to reduced mortality. Diabetes Metab.46(6), 423–426 (2020).
   PubMed Web of Science ®Google Scholar
• Malhotra A , HepokoskiM, MccowenKC, ShyyJY. ACE2, metformin, and COVID-19. Iscience23(9), 101425 (2020).
   PubMed Web of Science ®Google Scholar
• El-Arabey AA , AbdallaM. Metformin and COVID-19: a novel deal of an old drug. J. Med. Virol.92(11), 2293–2294 (2020).
   PubMed Web of Science ®Google Scholar
• Singh AK , SinghR. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?Diabetes Res. Clin. Pract.65, 108268 (2020).
   Google Scholar
• Bramante CT , IngrahamNE, MurrayTAet al. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev.2(1), e34–e41 (2021).
   PubMedGoogle Scholar
• Luo P , QiuL, LiuYet al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am. J. Trop. Med. Hyg.103(1), 69–72 (2020).
   PubMed Web of Science ®Google Scholar
• Kaye RJ . Overview of stem cell therapy for acute respiratory distress syndrome with focus on COVID-19. Pain Physician23, S425–S434 (2020).
   Web of Science ®Google Scholar
• Khorshidi M , ZarezadehM, EmamiM, OlangB, MoghaddamOM. Promising impacts of mesenchymal stem cell therapy in treatment of SARS-CoV-2 (COVID-19). Heart Lung49(6), 745–748 (2020).
   PubMed Web of Science ®Google Scholar
• Metcalfe SM . Mesenchymal stem cells and management of COVID-19 pneumonia. Med. Drug Discov.5, 100019 (2020).
   PubMedGoogle Scholar
• Meng F , XuR, WangSet al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct. Target Ther.5(1), 172 (2020).
   PubMed Web of Science ®Google Scholar
• Shetty AK . Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia. Aging Dis.11(2), 462–464 (2020).
   PubMed Web of Science ®Google Scholar
• Chen X , ShanY, WenY, SunJ, DuH. Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects. J. Infect.81(4), 647 (2020).
   Web of Science ®Google Scholar
• COVID-19 Treatment Guidelines Panel . Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health (2021). http://www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• Tu Y-F , ChienC-S, YarmishynAAet al. A review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci.21(7), 2657 (2020).
   PubMed Web of Science ®Google Scholar